Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, is a lifelong condition that disrupts the gastrointestinal tract and significantly impacts quality of life. While IBD has no…
During the REPREVIO clinical study, researchers sought to understand whether using vedolizumab (Entyvio) after bowel resection could prevent the risk of recurrence in individuals with advanced Crohn’s disease. Participants were…
Takeda Pharmaceuticals has recently announced the results from their open-label extension study, titled VISIBLE, which evaluates Entyvio as a treatment for ulcerative colitis. According to BioSpace, these results maintain the…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
